Skip to main content

Table 2 Surveillance for hepatotoxicity during follow-up period among treatment episodes

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Drug Treatment episodes Cumulative events within 12 months (%) * Episodes in which any ALT testing occurred during follow - up period Event rates for hepatotoxicity
0 - 3 month (%) Ϯ 3 - 6 month (%) Ϯ 6 - 12 month (%) Ϯ 0 - 3 month events (% ) Ŧ 3 - 6 month events (%) Ŧ 6 - 12 month events (%) Ŧ
Biologic agents 309 8 271 201 179 4 3 1
Abatacept 27 2 (7.4) 24 (88.9) 21 (77.8) 18 (66.7) 0 (0) 1 (4.8) 1 (5.6)
Adalimumab 116 2 (1.7) 103 (88.8) 77 (66.4) 74 (63.8) 1 (1.0) 1 (1.3) 0 (0)
Etanercept 113 3 (2.7) 92 (81.4) 70 (61.9) 65 (57.5) 2 (2.2) 1 (1.4) 0 (0)
Infliximab 29 0 (0) 28 (96.6) 18 (62.1) 14 (48.3) 0 (0) 0 (0) 0 (0)
Rituximab 24 1 (4.2) 24 (100) 15 (62.5) 8 (33.3) 1 (4.2) 0 (0) 0 (0)
Nonbiologic agents 650 18 524 373 317 9 4 5
Leflunomide 110 3 (2.7) 93 (84.5) 71 (64.5) 50 (45.5) 1 (1.1) 1 (1.4) 1 (2.0)
Methotrexate 183 8 (4.4) 163 (89.1) 113 (61.7) 103 (56.3) 3 (1.8) 1 (0.9) 4 (3.9)
Sulfasalazine-Hydroxychloroquine 357 7 (2.2) 268 (75.1) 189 (52.9) 164 (45.9) 5 (1.9) 2 (1.1) 0 (0)
TOTAL (% of total episodes) 959 26 (2.7) 795 (82.9) 574 (59.9) 496 (51.7) 13 (1.6) 7 (1.2) 6 (1.2)
  1. *Hepatotoxic events in time period divided by treatment episodes for drug listed in row; Ϯrepresents episodes that had at least one ALT test performed in given follow-up time period. Summation of three columns will exceed the total episodes, since an ALT could be performed in all three follow-up periods, unless censuring occurred (failure or end of follow-up period). ŦEvent rate percentage equals the number of hepatotoxicity events in time period divided by the number of ALT tests performed in same time period for drug row. ALT, alanine aminotransferase.